投資家はアボットとアブロビーの賭けを調整し、双方が強い収入と配当を報告した。 Investors adjust stakes in Abbott and AbbVie, both of which reported strong earnings and dividends.

いくつかの機関投資家は最近,医療企業であるアボット研究所とアボヴィー社における株式を調整した. ハレル保険投資はアボットの1,458株を購入し,合計2,451株で,価値は325,000ドルとなった. Several institutional investors have recently adjusted their stakes in healthcare companies Abbott Laboratories and AbbVie Inc. Harel Insurance Investments bought 1,458 shares of Abbott, bringing its total to 2,451 shares, valued at $325,000. Novare Capital ManagementはAbbottの持ち株を1.9%減らし、Concurrent Investment AdvisorsはAbbVieの持ち株を26.5%増やし、現在93,773株を保有しています。 Novare Capital Management reduced its holdings in Abbott by 1.9%, while Concurrent Investment Advisors increased its holdings in AbbVie by 26.5%, now owning 93,773 shares. 両社は,アボットが予想を上回り,四半期配当を0.59ドルと宣言した. Both companies reported strong earnings, with Abbott exceeding expectations and declaring a $0.59 quarterly dividend. AbbVieも収益の見積りを超え,第64回四半期の配当額を発表した. AbbVie also surpassed earnings estimates and announced a $1.64 quarterly dividend.